相似文献
1
CRISPRed Macrophages for Cell-Based Cancer Immunotherapy.
Bioconjug Chem. 2018 Feb 21;29(2):445-450. doi: 10.1021/acs.bioconjchem.7b00768. Epub 2018 Jan 22.
2
[Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
Zhonghua Shao Shang Za Zhi. 2018 Apr 20;34(4):253-256. doi: 10.3760/cma.j.issn.1009-2587.2018.04.013.
3
LeishGEdit: A Method for Rapid Gene Knockout and Tagging Using CRISPR-Cas9.
Methods Mol Biol. 2019;1971:189-210. doi: 10.1007/978-1-4939-9210-2_9.
4
Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9.
Protein Cell. 2017 Sep;8(9):634-643. doi: 10.1007/s13238-017-0410-x. Epub 2017 Apr 22.
5
Efficient CRISPR-mediated mutagenesis in primary immune cells using CrispRGold and a C57BL/6 Cas9 transgenic mouse line.
Proc Natl Acad Sci U S A. 2016 Nov 1;113(44):12514-12519. doi: 10.1073/pnas.1613884113. Epub 2016 Oct 11.
6
Recent advances in CRISPR/Cas9 mediated genome editing in Bacillus subtilis.
World J Microbiol Biotechnol. 2018 Sep 29;34(10):153. doi: 10.1007/s11274-018-2537-1.
7
A Toolkit of CRISPR-Based Genome Editing Systems in Drosophila.
J Genet Genomics. 2015 Apr 20;42(4):141-9. doi: 10.1016/j.jgg.2015.02.007. Epub 2015 Mar 12.
8
In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
Bioconjug Chem. 2017 Apr 19;28(4):880-884. doi: 10.1021/acs.bioconjchem.7b00057. Epub 2017 Mar 17.
9
Application of CRISPR/Cas9 Genome Editing to Improve Recombinant Protein Production in CHO Cells.
Methods Mol Biol. 2017;1603:101-118. doi: 10.1007/978-1-4939-6972-2_7.
10
The CRISPR System and Cancer Immunotherapy Biomarkers.
Methods Mol Biol. 2020;2055:301-322. doi: 10.1007/978-1-4939-9773-2_14.
引用本文的文献
1
Nanoparticles for Cancer Immunotherapy: Innovations and Challenges.
Pharmaceuticals (Basel). 2025 Jul 22;18(8):1086. doi: 10.3390/ph18081086.
2
Focusing on the interplay between tumor-associated macrophages and tumor microenvironment: from mechanism to intervention.
Theranostics. 2025 Jun 20;15(15):7378-7408. doi: 10.7150/thno.113727. eCollection 2025.
3
Bioengineered therapeutic systems for improving antitumor immunity.
Natl Sci Rev. 2024 Nov 12;12(1):nwae404. doi: 10.1093/nsr/nwae404. eCollection 2025 Jan.
4
Are monocytes a preferable option to develop myeloid cell-based therapies for solid tumors?
J Exp Clin Cancer Res. 2025 Mar 15;44(1):98. doi: 10.1186/s13046-025-03359-x.
5
Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond.
Front Immunol. 2025 Feb 19;16:1544532. doi: 10.3389/fimmu.2025.1544532. eCollection 2025.
6
Advances in CRISPR-Cas technology and its applications: revolutionising precision medicine.
Front Genome Ed. 2024 Dec 12;6:1509924. doi: 10.3389/fgeed.2024.1509924. eCollection 2024.
7
Nanotherapeutics for Macrophage Network Modulation in Tumor Microenvironments: Targets and Tools.
Int J Nanomedicine. 2024 Dec 19;19:13615-13651. doi: 10.2147/IJN.S491573. eCollection 2024.
8
Empowering brain tumor management: chimeric antigen receptor macrophage therapy.
Theranostics. 2024 Sep 3;14(14):5725-5742. doi: 10.7150/thno.98290. eCollection 2024.
9
Tumor‑associated macrophages activated in the tumor environment of hepatocellular carcinoma: Characterization and treatment (Review).
Int J Oncol. 2024 Oct;65(4). doi: 10.3892/ijo.2024.5688. Epub 2024 Sep 6.
10
[Research progress of CAR-macrophages in malignant hematological diseases].
Zhonghua Xue Ye Xue Za Zhi. 2024 Apr 14;45(4):413-416. doi: 10.3760/cma.j.cn121090-20231103-00248.
本文引用的文献
1
SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin.
Nature. 2017 Apr 27;544(7651):493-497. doi: 10.1038/nature22076. Epub 2017 Apr 19.
2
In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
Bioconjug Chem. 2017 Apr 19;28(4):880-884. doi: 10.1021/acs.bioconjchem.7b00057. Epub 2017 Mar 17.
3
Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing.
ACS Nano. 2017 Mar 28;11(3):2452-2458. doi: 10.1021/acsnano.6b07600. Epub 2017 Jan 31.
4
CRISPR-Cas9: Prospects and Challenges.
Hum Gene Ther. 2015 Jul;26(7):409-10. doi: 10.1089/hum.2015.29002.fzh.
5
Quantitative tracking of protein trafficking to the nucleus using cytosolic protein delivery by nanoparticle-stabilized nanocapsules.
Bioconjug Chem. 2015 Jun 17;26(6):1004-7. doi: 10.1021/acs.bioconjchem.5b00141. Epub 2015 Jun 2.
6
"Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
J Biol Chem. 2015 May 15;290(20):12650-63. doi: 10.1074/jbc.M115.648220. Epub 2015 Apr 2.
7
Addressing the Inflammatory Response to Clinically Relevant Polymers by Manipulating the Host Response Using ITIM Domain-Containing Receptors.
Polymers (Basel). 2014 Sep 29;6(10):2526-2551. doi: 10.3390/polym6102526.
8
The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target.
Annu Rev Immunol. 2014;32:25-50. doi: 10.1146/annurev-immunol-032713-120142. Epub 2013 Nov 6.
9
Genome engineering using the CRISPR-Cas9 system.
Nat Protoc. 2013 Nov;8(11):2281-2308. doi: 10.1038/nprot.2013.143. Epub 2013 Oct 24.
10
Targeting tumor-infiltrating macrophages to combat cancer.
Immunotherapy. 2013 Oct;5(10):1075-87. doi: 10.2217/imt.13.102.
Zotero 插件